Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTR1E | P28566 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634148 | 0.96 | LMNA (0.44) | LMNAHTR1ES1PR3MEN1MAPT | |
| SCHEMBL28756913 | 0.86 | SLC6A3 (0.57) | LMNAHTR1ES1PR3MEN1MAPT | |
| SCHEMBL4682197 | 0.83 | CYP2D6 (0.45) | LMNAHTR1ES1PR3MEN1MAPT | |
| SCHEMBL3959104 | 0.83 | OPRM1 (0.42) | MEN1KMT2ASLC6A3SLC6A2SLC6A4 | |
| SCHEMBL28622389 | 0.79 | HTR1E (0.65) | LMNAHTR1ES1PR3MEN1MAPT | |
| SCHEMBL69127 | 0.79 | HTR1E (0.65) | LMNAHTR1ES1PR3MEN1MAPT | |
| SCHEMBL12531975 | 0.78 | HTR1E (0.63) | LMNAHTR1ES1PR3MEN1MAPT | |
| SCHEMBL67219 | 0.78 | HTR1E (0.63) | LMNAHTR1ES1PR3MEN1MAPT | |
| Hydrochloric Acid SCHEMBL11526873 | 0.76 | HTR1E (0.61) | LMNAHTR1ES1PR3MEN1MAPT | |
| SCHEMBL7799095 | 0.76 | CYP3A4 (0.47) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084827-B2 | Biodegradable polyurethane/urea compositions | POLYNOVO BIOMATERIALS PTY LIMITED (AU) | 2015-07-21 | — | — | US | claimed |
| US-20140099277-A1 | BIODEGRADABLE POLYURETHANE/UREA COMPOSITIONS | POLYNOVO BIOMATERIALS PTY LIMITED (AU) | 2014-04-10 | — | — | US | claimed |
| US-20130150964-A1 | BIODEGRADABLE POLYURETHANE/UREA COMPOSITIONS | POLYNOVO BIOMATERIALS PTY LIMITED (AU) | 2013-06-13 | — | — | US | claimed |
| EP-2177511-A2 | Process for preparing 3,6-disubstituted azabicyclo derivatives | Ranbaxy Laboratories Limited (IN) | 2010-04-21 | — | — | EP | disclosed |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | US | disclosed |
| EP-2059505-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2009-05-20 | — | — | EP | disclosed |
| EP-1546099-B1 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-12-31 | — | — | EP | disclosed |
| US-7399779-B2 | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-07-15 | — | — | US | disclosed |
| EP-1572648-B1 | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)-HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-07-09 | — | — | EP | disclosed |
| EP-1546098-B1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008029349-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2008-03-13 | — | — | WO | disclosed |
| EP-1546098-A4 | 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0|HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-08-23 | — | — | EP | disclosed |
| EP-1546099-A4 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | EP | disclosed |
| US-20060122253-A1 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-08 | — | — | US | disclosed |
| EP-1572648-A1 | 3,6-DISUBSTITUTED AZABICYCLO (3.1.0)-HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-09-14 | — | — | EP | disclosed |
| EP-1546099-A2 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| EP-1546098-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004052857-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004014853-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004004629-A2 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140099277-A1 | BIODEGRADABLE POLYURETHANE/UREA COMPOSITIONS | PUF60, UMPS, COL2A1 | LMNA 82/4885HTR1E 3746/4885S1PR3 2160/4885 |
| US-20060122253-A1 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | LMNA 4106/4885HTR1E 127/4885S1PR3 162/4885 |
| US-20100056496-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | LMNA 3063/4885HTR1E 213/4885S1PR3 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.